Search Results
501 results
Your search is now limited to «Leukemia» expert search.
ClinicalTrials.gov 03/20/2019 10:36
Condition : Chronic Myeloid Leukemia, Chronic Phase Intervention : Drug: HQP1351 Sponsor : Ascentage Pharma Group Inc. Not yet recruiting.
More from ClinicalTrials.gov:
WN.com 03/19/2019 12:42
The study suggests that targeting EZH2 could therefore be an effective treatment for AML, an aggressive blood cancer expected to kill over 10,000 people in the US alone this year.
More from WN.com:
ecancer news 03/19/2019 09:21
The study, published in the Journal of Experimental Medicine, suggests that targeting EZH2 could therefore be an effective treatment for AML, an aggressive blood cancer expected to kill over 10,000 people in the US alone this year.
More from ecancer news:
ScienceDaily 03/19/2019 09:20
Researchers have discovered that an epigenetic protein called EZH2 delays the development of acute myeloid leukemia (AML) but then switches sides once the disease is established to help maintain tumor growth. The study suggests that targeting EZH2 could therefore be an effective treatment for AML, an aggressive blood cancer expected to kill over 10,000 people in the US alone this year.
More from ScienceDaily:
Stem Cells Portal 03/18/2019 09:15
The team’s finding that Ragnase-1 plays a key role in the self-renewal and differentiation of HSPCs provides a new target for therapeutic strategies aimed at treating diseases such as leukemia.
More from Stem Cells Portal:
PubMed News (NIH) 03/18/2019
Status Public on Mar 18, 2019 Title miR-7977 transfer alter the transcriptome in bone marrow mesenchymal stem cells.
More from PubMed News (NIH):
Purpose:. Although myeloablative HLA haploidentical hematopoietic stem cell transplantation (haplo-HSCT) following pretransplant anti-thymocyte globulin (ATG) and granulocyte colony-stimulating factor (G-CSF) stimulated grafts (ATG+G-CSF) has been confirmed as an alternative to HSCT from HLA-matched sibling donors (MSD), the effect of haplo-HSCT on postremission treatment of patients with acute myeloid leukemia (AML) with intermediate risk (int-risk AML) who achieved first complete remission (CR1) has not been defined. Patients and Methods:. In this prospective trial, among 443 consecutive patients ages 16–60 years with newly diagnosed de no vo AML with int-risk cytogenetics, 147 patients with molecular int-risk AML who achieved CR1 within tw.
More from Clinical Cancer Research - Recent Issues (abstracts):
The apoptosis repressor with caspase recruitment domain (ARC) protein is a strong independent adverse prognostic marker in acute myeloid leukemia (AML). We previously reported that ARC regulates leukemia–microenvironment interactions through the NFκB/IL1β signaling network. Malignant cells have been reported to release IL1β, which induces PGE2 synthesis in mesenchymal stromal cells (MSC), in turn activating β-catenin signaling and inducing the cancer stem cell phenotype. Although Cox-2 and its enzymatic product PGE2 play major roles in inflammation and cancer, the regulation and role of PGE2 in AML are largely unknown. Here, we report that AML–MSC cocultures greatly increase Cox-2 expression in MSC and PGE2 production in an ARC/IL1β–depende.
More from Cancer Research - Recent Issues (abstracts):
Most people infected with the virus never develop symptoms, but some develop terrible illnesses, like deadly blood cancer or a debilitating nervous system condition.
More from Middle East North Africa Financial Network (MENAFN):
Clinical Epigenetics 03/14/2019 20:00
The delta-like non-canonical Notch ligand 1 (DLK1)-maternally expressed 3(MEG3) locus (DLK1-MEG3 locus) plays a critical role in the maintenance and differentiation of hematopoietic stem cells. Accumulating evide...
More from Clinical Epigenetics:
The Quint - India 03/14/2019 16:57
Most people infected with the virus never develop symptoms, but some develop terrible illnesses, like a deadly blood cancer or a debilitating nervous system condition.
More from The Quint - India:
Healio News 03/14/2019 16:55
Ian W. Flinn The combination of venetoclax and obinutuzumab conferred high response rates with deep remissions among patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia, according to results of a single-arm, phase 1b trial published in Blood.
More from Healio News:
PR Newswire 03/14/2019 12:00
From The Leukemia & Lymphoma Society's beginning 70 years ago with the development of new treatments for childhood leukemia to today's advances in precision medicine and immunotherapy, LLS has led the way in changing the way we treat cancer and care for patients ...
More from PR Newswire:
FoxNews (United States) 03/13/2019 12:57
In a report released on Wednesday, March 13, 2019, researchers say self-flagellation should be added to the list of ways to spread a dangerous viral blood infection.
More from FoxNews (United States):
Credit: Osaka University "Our findings showed that the deletion of both or even just one of the copies of Ragnase-1 led to abnormalities in the renewal and differentiation of HSPCs from the bone marrow," corresponding author Nobuyuki Takakura says.
More from Medical Xpress - Medical Research News:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications